Novanta: A Quiet Investment

by

A curious transaction occurred on February 13th. ACK Asset Management, a fund not given to rashness, allotted some $44.62 million to Novanta, acquiring 375,000 shares. One imagines the portfolio manager, a man likely burdened with spreadsheets and the quiet desperation of quarterly reports, saw something… promising. Or perhaps merely acceptable.

A Modest Addition

The SEC filing confirms the purchase, a significant, though not extravagant, addition to ACK’s holdings. It represents 5.6% of their 13F AUM – a noticeable commitment, certainly, but one that doesn’t exactly set the financial world ablaze. One wonders if the decision was made over lukewarm coffee and a shared sigh regarding the current market conditions.

Their larger holdings, as of the same filing, remain comfortably established: Materion at $59.03 million, Granite Construction at $57.67 million, and so on. Novanta joins a stable, if unexciting, company. A quiet neighbor in a well-ordered portfolio.

As of February 12th, Novanta shares traded at $139.29 – a price that has, over the past year, demonstrated a certain… reluctance to ascend. A decline of 5.7% feels less like a failure, and more like a gentle settling. It underperforms the S&P 500 by a margin of 18.63 percentage points, a statistic that, when considered alongside the grand sweep of history, feels rather… insignificant.

The Company Itself

Metric Value
Revenue (TTM) $960.31 million
Net income (TTM) $52.82 million
Price (as of market close February 12, 2026) $139.29
One-year price change (5.73%)

Novanta, one gathers, designs and manufactures components – photonics, vision systems, precision motion – for those who require such things. They supply OEMs, primarily in the medical and industrial sectors. A respectable business, certainly. It is a world of gears and lasers, of exacting tolerances and quiet efficiency. A world far removed from the headlines and the grand pronouncements of Silicon Valley.

They boast a diversified product portfolio and global distribution channels. Nearly $1 billion in trailing twelve-month revenue is no small feat. They leverage proprietary technologies and brands. They address mission-critical applications. All the proper terms are used. One can almost feel the weight of expectation, the silent pressure to innovate and deliver.

A Question of Momentum

High-precision component suppliers, it is often observed, do not always receive the credit they deserve when broader markets falter. A disconnect, perhaps, between technical proficiency and investor enthusiasm. And in that disconnect, as the saying goes, lies opportunity. Though what form that opportunity will take remains, as always, uncertain.

Third quarter revenue came in at $247.8 million, up a modest 1.4% year over year. Adjusted EBITDA ticked up, to $58.1 million. Adjusted EPS reached $0.87. Guidance for the full year 2025 anticipates revenue of $975 million to $979 million. Free cash flow, however, was modest – $4.2 million – weighed down by inventory and restructuring. These are the details, the small victories and quiet setbacks that constitute the life of a company.

At 5.6% of assets, this is a significant allocation for ACK, particularly given their existing tilt toward industrial and infrastructure names. The key question, of course, is whether organic growth will reaccelerate as medical and advanced industrial demand recovers. It is a question that has been asked before, and will likely be asked again. The market, after all, rarely offers easy answers.

One suspects that life will simply continue, as it always does. Novanta will manufacture its components, ACK will manage its portfolio, and the world will slowly turn. And in the quiet spaces between the numbers and the pronouncements, a faint melancholy will linger, a sense that something is always just out of reach.

Read More

2026-02-14 22:15